BIOFRONTERA AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.312 EUR | 0.00% |
|
+6.85% | -23.90% |
| Apr. 30 | Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Mar. 11 | Biofrontera Files Prospectus for Potential Secondary Stock Offerings | MT |
| Sales 2022 | 25.74M 27.7M | Sales 2023 | 32.25M 34.7M | Capitalization | 25.59M 27.53M |
|---|---|---|---|---|---|
| Net income 2022 | -44M -47.35M | Net income 2023 | - 0 | EV / Sales 2022 | 3.59 x |
| Net cash position 2022 | 4.88M 5.25M | Net cash position 2023 | 1.93M 2.08M | EV / Sales 2023 | 0.73 x |
| P/E ratio 2022 |
-1.98
x | P/E ratio 2023 |
-40.1
x | Employees | 92 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 32.4% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biofrontera AG
More press releases
| 1 week | +6.85% | ||
| Current month | -13.81% | ||
| 1 month | -6.02% | ||
| 3 months | -26.76% | ||
| 6 months | -37.60% | ||
| Current year | -23.90% |
1 week
0.29
0.36
1 month
0.290.37
Current year
0.290.55
1 year
0.291.14
3 years
0.293.14
5 years
0.298.13
10 years
0.298.13
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | 55 | 22-09-11 | |
Anke zur Muehlen
IRO | Public Communications Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 63 | 21-12-13 | |
| Director/Board Member | - | 21-12-13 | |
Heikki Lanckriet
BRD | Director/Board Member | 47 | 21-12-13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 0.312 | 0.00% | 0 |
| 24-05-02 | 0.312 | -13.81% | 0 |
| 24-04-30 | 0.362 | +23.97% | 0 |
| 24-04-29 | 0.292 | 0.00% | 0 |
| 24-04-26 | 0.292 | -13.61% | 0 |
Delayed Quote Deutsche Boerse AG, May 03, 2024 at 02:00 am EDT
More quotes
Biofrontera AG is a Germany-based biopharmaceutical company. The Company develops drugs and medicinal cosmetics for the treatment of skin diseases and regenerative care of damaged skin. Its portfolio includes: Ameluz, for photodynamic therapy (PDT) of actinic keratoses, and under development for other types of skin cancer and warts; PDT lamp BF-RhodoLED, used after the Ameluz treatment to eliminate infected cells; and Belixos, a dermatological cream with herbal ingredients for the care of itching, inflamed and flaky skin and conditions such as insect bites, burns, neurodermatitis and psoriasis. The Company is also engaged in clinical development of two drug candidates: BF-derm1, a tablet with inhibitor blocking the synthesis of histamine in cells, a cause of allergic reactions; and BF1, a selective serotonin receptor to prevent migraines. The Company operates five wholly owned subsidiaries, notably Biofrontera Inc in the United States. Its main shareholder is MM Familien KG.
Sector
Pharmaceuticals
Calendar
2024-05-28
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +26.08% | 662B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B |
- Stock Market
- Equities
- B8F Stock
- B8F Stock
